Captieux M, Prigge R, Wild S, Guthrie B. Defining remission of type 2 diabetes in research studies: a systematic scoping review. PLoS Med. 2020;17(10):e1003396.

Article  PubMed  PubMed Central  Google Scholar 

American Diabetes Association Professional Practice Committee, ElSayed NA, Aleppo G, et al. 10. Cardiovascular disease and risk management: standards of care in diabetes—2024. Diabetes Care. 2024;47(Supplement_1):S179-218.

Article  Google Scholar 

American Diabetes Association Professional Practice Committee, ElSayed NA, Aleppo G, et al. 1. Improving care and promoting health in populations: standards of care in diabetes—2024. Diabetes Care. 2024;47(Supplement_1):S11–9.

Article  Google Scholar 

Ahlqvist E, Prasad RB, Groop L. Subtypes of type 2 diabetes determined from clinical parameters. Diabetes. 2020;69(10):2086–93.

Article  PubMed  Google Scholar 

McInnes N, Smith A, Otto R, et al. Piloting a remission strategy in type 2 diabetes: results of a randomized controlled trial. J Clin Endocrinol Metab. 2017;102(5):1596–605.

Article  PubMed  Google Scholar 

Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2013;1(1):28–34.

Article  PubMed  Google Scholar 

McInnes N, Hall S, Lochnan HA, et al. Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: results of a randomised controlled trial. Diabetes Obes Metab. 2023;25(11):3347–55.

Article  PubMed  Google Scholar 

Kramer CK, Zinman B, Choi H, Retnakaran R. Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes. BMJ Open Diab Res Care. 2016;4(1):e000270.

Article  PubMed  PubMed Central  Google Scholar 

Lunati ME, Cimino V, Bernasconi D, et al. Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide. Pharmacol Res. 2024;199:107040.

Article  PubMed  Google Scholar 

Riddle MC, Cefalu WT, Evans PH, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetes Care. 2021;44(10):2438–44.

Article  PubMed  PubMed Central  Google Scholar 

Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32(11):2133–5.

Article  PubMed  PubMed Central  Google Scholar 

Zhou X, Zeng C. Diabetes remission of bariatric surgery and nonsurgical treatments in type 2 diabetes patients who failure to meet the criteria for surgery: a systematic review and meta-analysis. BMC Endocr Disord. 2023;23(1):46.

Article  PubMed  PubMed Central  Google Scholar 

Bays H, Abate N, Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia. Future Cardiol. 2005;1(1):39–59.

Article  PubMed  Google Scholar 

Wu H, Ballantyne CM. Metabolic inflammation and insulin resistance in obesity. Circ Res. 2020;126(11):1549–64.

Article  PubMed  PubMed Central  Google Scholar 

Ren J, Wu NN, Wang S, Sowers JR, Zhang Y. Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications. Physiol Rev. 2021;101(4):1745–807.

Article  PubMed  PubMed Central  Google Scholar 

Ray I, Mahata SK, De RK. Obesity: an immunometabolic perspective. Front Endocrinol. 2016. https://doi.org/10.3389/fendo.2016.00157/full.

Article  Google Scholar 

Engin AB, Engin A, editors. The pathogenesis of obesity-associated adipose tissue inflammation. 2017;960. https://doi.org/10.1007/978-3-319-48382-5

McManus DD, Lyass A, Ingelsson E, et al. Relations of circulating resistin and adiponectin and cardiac structure and function: the Framingham offspring study. Obesity. 2012;20(9):1882–6.

Article  PubMed  Google Scholar 

Kim M, Oh JK, Sakata S, et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol. 2008;45(2):270–80.

Article  PubMed  PubMed Central  Google Scholar 

Zhou Y, Yu X, Chen H, et al. Leptin deficiency shifts mast cells toward anti-inflammatory actions and protects mice from obesity and diabetes by polarizing M2 macrophages. Cell Metab. 2015;22(6):1045–58.

Article  PubMed  PubMed Central  Google Scholar 

Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014;371(12):1131–41.

Article  PubMed  Google Scholar 

Di Chiara T, Argano C, Corrao S, Scaglione R, Licata G. Hypoadiponectinemia: a link between visceral obesity and metabolic syndrome. J Nutr Metab. 2012;2012:1–7.

Article  Google Scholar 

Corrao S, Calvo L, Amico S, Argano C. The critical role of abdominal obesity as a crucial cardiovascular risk factor. Diabetes Obes Metab. 2024;26(5):1967–70.

Article  PubMed  Google Scholar 

Arner P, Kulyté A. MicroRNA regulatory networks in human adipose tissue and obesity. Nat Rev Endocrinol. 2015;11(5):276–88.

Article  PubMed  Google Scholar 

Atkin SL, Ramachandran V, Yousri NA, et al. Changes in blood microRNA expression and early metabolic responsiveness 21 days following bariatric surgery. Front Endocrinol. 2019;4(9):773.

Article  Google Scholar 

Tilg H, Zmora N, Adolph TE, Elinav E. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol. 2020;20(1):40–54.

Article  PubMed  Google Scholar 

Canfora EE, Meex RCR, Venema K, Blaak EE. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol. 2019;15(5):261–73.

Article  PubMed  Google Scholar 

Chong S, Lin M, Chong D, Jensen S, Lau NS. A systematic review on gut microbiota in type 2 diabetes mellitus. Front Endocrinol. 2025;17(15):1486793.

Article  Google Scholar 

Fasano A. The physiology of hunger. N Engl J Med. 2025;392(4):372–81.

Article  PubMed  Google Scholar 

Davies N, O’Sullivan JM, Plank LD, Murphy R. Gut microbial predictors of type 2 diabetes remission following bariatric surgery. Obes Surg. 2020;30(9):3536–48.

Article  PubMed  Google Scholar 

Kinoshita K, Ozato N, Yamaguchi T, et al. Association of the gut microbiota with type 2 diabetes: links to disease and remission in the Japanese population. 2025. J Diabetes Investig. https://doi.org/10.1111/jdi.70061.

Hernández-Montoliu L, Rodríguez-Peña MM, Puig R, et al. A specific gut microbiota signature is associated with an enhanced GLP-1 and GLP-2 secretion and improved metabolic control in patients with type 2 diabetes after metabolic Roux-en-Y gastric bypass. Front Endocrinol. 2023;17(14):1181744.

Article  Google Scholar 

Bays H. Adiposopathy, “sick fat”, Ockham’s razor, and resolution of the obesity paradox. Curr Atheroscler Rep. 2014;16(5):409.

Article  PubMed  PubMed Central  Google Scholar 

Sattar N, Gill JM. Type 2 diabetes as a disease of ectopic fat? BMC Med. 2014;12(1):123.

Article  PubMed  PubMed Central  Google Scholar 

Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011;54(10):2506–14.

Article  PubMed  PubMed Central  Google Scholar 

Soare A, Del Toro R, Roncella E, et al. The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial. BMJ Open Diab Res Care. 2015;3(1):e000079.

Article  PubMed  PubMed Central  Google Scholar 

Taheri S, Zaghloul H, Chagoury O, , et al. Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol. 2020;8(6):477–89.

Article  PubMed